Interviews
View More
Greenleaf: Most Republicans View Kennedy as Qualified to Lead HHS

Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.

Special Considerations When Utilizing Neurokinin-Targeted Therapies

A panelist discusses how she navigates the economic challenges of neurokinin-targeted therapies by working with insurance providers and patient assistance programs while advocating for expanded access among underserved populations who may particularly benefit from these treatment options.

The HIV Epidemic in Trump’s America

Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

One Institution’s Evidence-Based Approach to Adopting Biosimilars

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.

Potential Impact of Emerging PPF Treatments on Patient Outcomes and Health Ccare Resource Utilization

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved, exploring how they could address key unmet needs, improve patient outcomes, and optimize healthcare resource utilization.

Emerging Therapies for PPF

Panelists provide an overview of emerging therapies for progressive pulmonary fibrosis (PPF), highlighting the latest developments and potential treatment options.

Key Unmet Needs in PPF Management

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and how ongoing research and collaborative efforts may help address these challenges.

Incorporating Neurokinin-Targeted Therapies Into Patient Care Plans

A panelist discusses how she proactively addresses safety concerns about neurokinin-targeted therapies through evidence-based patient education and systematic monitoring while implementing streamlined protocols and documentation systems to effectively integrate these treatments into clinical workflow.

Evaluating Neurokinin-Targeted Therapies for Vasomotor Symptoms (VMS)

A panelist discusses how she carefully transitions patients to neurokinin-targeted therapies by establishing realistic timelines for symptom improvement and actively monitoring patient response while providing education about potential benefits and limitations of the new treatment approach.

Official Media Partners

PBMI logo

Join the Community

an mjh life sciences brand

© 2022 MJH Life Sciences® and PBMI. All rights reserved.